Distinct patterns of antiamyloid-β antibodies in typical and atypical Alzheimer disease

Guillaume Dorothée 1 Michel Bottlaender 2, 3 Edmond Moukari 1 Leonardo C De Souza 4 Renaud Maroy 3 Fabian Corlier 4 Olivier Colliot 5, 6 Marie Chupin 6, 5 Foudil Lamari 5, 7 Stephane Lehéricy 4 Bruno Dubois 4 Marie Sarazin 4 Pierre Aucouturier 1
1 Inserm UMR_S 938 - Pathologies biliaires, fibrose et cancer du foie
CR Saint-Antoine - Centre de Recherche Saint-Antoine, CHU Saint-Antoine [APHP]
2 NEUROSPIN - Service NEUROSPIN
3 SHFJ - Service Hospitalier Frédéric Joliot
4 CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière
5 ARAMIS - Algorithms, models and methods for images and signals of the human brain
Inria Paris-Rocquencourt, UPMC - Université Pierre et Marie Curie - Paris 6, ICM - Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute
6 NEMESIS-CRICM - Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière
CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière
7 Service de Biochimie Métabolique [CHU Pitié-Salpêtrière]
Abstract : OBJECTIVE: To compare serum antiamyloid-β (Aβ) antibodies in typical and atypical Alzheimer disease (AD). DESIGN: Preliminary observations. SUBJECTS: Thirteen patients with AD, 8 patients with posterior cortical atrophy with evidence of AD (PCA-AD) pathophysiological process by both cerebrospinal fluid (CSF) biomarkers and amyloid imaging, and 12 age-matched control individuals. INTERVENTIONS: The class and subclass levels of serum anti-Aβ antibodies were measured using an oligomer-based enzyme-linked immunosorbent assay. This method allowed measuring both free antibodies and, after acidic treatment, the total fraction that includes all antibodies complexed with circulating Aβ40/42 and any cross-reacting antigen. RESULTS: Anti-Aβ IgG were restricted to the IgG1 and IgG3 subclasses. Their total levels were strikingly lower and more homogeneous in patients with PCA compared with both typical AD and controls, while biomarkers of amyloid deposition (CSF Aβ42 and positron emission tomography amyloid imaging) were similar in patients with AD and patients with PCA. CONCLUSIONS: Serum anti-Aβ IgG1 and IgG3 antibodies differ between distinct forms of AD. Its significance is discussed for possible implications as immune effectors in the specific pathophysiology of AD variants.
Keywords : Degenerative disease Central nervous system disease Nervous system diseases Cerebral disorder Alzheimer disease
Type de document :
Article dans une revue
Archives of Neurology -Chigago-, American Medical Association, 2012, 69 (9), pp.1181-1185. 〈10.1001/archneurol.2012.604〉
Liste complète des métadonnées
https://hal.inria.fr/hal-00790083
Contributeur : Olivier Colliot <>
Soumis le : mardi 19 février 2013 - 13:55:47
Dernière modification le : mardi 17 avril 2018 - 11:28:17

Lien texte intégral

openaccess

Identifiants

Collections

U938 | INRIA | ICM | UPMC | ARAMISLAB | | CEA | JOLIOT | NEUROSPIN | SHFJ | CEA-DRF

Citation

Guillaume Dorothée, Michel Bottlaender, Edmond Moukari, Leonardo C De Souza, Renaud Maroy, et al.. Distinct patterns of antiamyloid-β antibodies in typical and atypical Alzheimer disease. Archives of Neurology -Chigago-, American Medical Association, 2012, 69 (9), pp.1181-1185. 〈10.1001/archneurol.2012.604〉. 〈hal-00790083〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

256

Contact


archive-ouverte@inria.fr